论文部分内容阅读
肺耐药相关蛋白(LRP)是与多药耐药(MDR)相关的糖蛋白。在儿童白血病及成人急性髓系白血病(AML)中,LRP 表达是独立的预后决定因素之一,其过度表达造成患者对化疗不敏感,提示预后不良。近年来,小分子干扰RNA (siRNA)介导的RNA干扰(RNAi)既可以特异地降解同源 mRNA序列,从而有效阻止相应蛋白质的表达,并且与相应的单链反义核酸相比,siRNA造成的基因抑制效率更高、特异性更好,所需有效浓度却大大减低。国内外学者将siRNA
Lung resistance drug-associated protein (LRP) is a glycoprotein associated with multidrug resistance (MDR). LRP expression is one of the independent prognostic factors in childhood leukemia and adult acute myeloid leukemia (AML), and its over-expression causes the patient to be chemotherapy-insensitive, suggesting a poor prognosis. In recent years, small interfering RNA (siRNA) -mediated RNA interference (RNAi) can both specifically degrade homologous mRNA sequences and thus effectively block the expression of the corresponding proteins, and the siRNAs cause The gene inhibition efficiency is higher, the specificity is better, the required effective concentration is greatly reduced. Domestic and foreign scholars will siRNA